Genomic Determinants and Antimicrobial Resistance Pattern of Clinical Isolates of Extended Spectrum Beta Lactamase (ESBL) Producing Escherichia coli

Hamid Ahmad Shah1*, Arshi Syed2, Mohd Altaf Bhat3, Dalip K. Kakru1, Shaheen Farooq4, Sabia Qureshi4, Azhar Shafi2, Burhan Nabi5 and Anil Taku6

1Department of Microbiology, SMSR, Sharda University, Greater Noida, Uttar Pradesh, India.
2Department of Microbiology SKIMS Medical College, Bemina, Srinagar, Jammu & Kashmir, India.
3Department of Veterinary Microbiology & Immunology, F.V.Sc & A.H., SKUAST-K, Shuhama, Srinagar, Jammu & Kashmir, India.
4Department of Microbiology & Immunology, F.V.Sc & A.H., SKUAST-K, Shuhama, Srinagar, Jammu & Kashmir, India.
5Department of Veterinary Medicine, Khalsa College of Veterinary and Animal Sciences, Amritsar, Punjab, India.
6Department of Veterinary Microbiology, F.V.Sc & A.H., SKUAST-Jammu, Jammu & Kashmir, India.

*Correspondence: syedhamydh@gmail.com
INTRODUCTION

Escherichia coli (E. coli) is one of the bacterial species of particular concern as a result of the rising incidence of antibiotic-resistant bacteria, which is a global public health issue. Both community-acquired and hospital associated infections are caused by this pathogen and have shown increasing resistance to third-generation cephalosporins, which can cause more expensive hospital stays, greater mortality and morbidity rates. The major challenge for the physicians nowadays is treating ESBL producing Strains. Extended-spectrum beta-lactamase (ESBL)-producing strains of E. coli have been discovered as a significant cause of antibiotic resistance. ESBLs are enzymes that render various beta-lactam antibiotics inactive including cephalosporins and monobactams. Due to the widespread usage of these antibiotics, resistance has emerged. Occurrence of carbapenem resistance is also rapidly increasing in E. coli due to the production of different types of enzymes called carbapenemases. These enzymes have potential to hydrolyze almost all beta-lactams, including carbapenem the genes of which are located on mobile genetic element (MGE) called plasmids. Due to the majority of cross resistance between beta-lactamases produced by Enterobacteriaceae and other classes of commonly used antibiotics, such as aminoglycosides, trimethoprim sulfamethoxazole, and fluoroquinolones, only a limited number of therapeutic options are available in a hospital setting. There is very high hospital stay expenses and high mortality rates associated with these multidrug resistant organisms in contrast to non beta-lactamase producing Enterobacteriaceae. Thus, the surveillance and monitoring of these beta-lactamase producing Enterobacteriaceae is important for clinical care. Three main types of ESBL’s have been recognized which are TEM, SHV, and CTX-M. In terms of prevalence, CTX-M has surpassed SHV and TEM. CTX-M belongs to rapidly growing family that has expanded over a variety of clinically significant bacteria and vast geographic regions. Understanding susceptibility patterns is important because of the rising rates of bacterial resistance which is a major global problem this is because prolonged hospital stays and higher mortality rates can result from the widespread and rapid increase of ESBL-producing Enterobacteriaceae.
inappropriate use of antimicrobial therapy which can be prevented by providing right treatment. In this investigation, the prevalence of the ESBL phenotype was attempted to be ascertained, and clinical isolates were examined for the presence of the $\text{bla}_{\text{TEM}}$, $\text{bla}_{\text{SHV}}$, and $\text{bla}_{\text{CTX-M}}$ genes.

**MATERIALS AND METHODS**

The study was carried out in department of veterinary microbiology SKUAST-K and department of microbiology SMSR, SU from Jan 2021 to Dec 2022. A total of 210 *E.coli* isolates from various samples collected from different location in the Kashmir valley and Noida UP region (Table 1). The source of these isolates includes urine, ear swab, and wound/pus swabs. These isolates were collected from patients with suspected *E.coli* infections. The contributing centres were department of Microbiology of the Sher-e-Kashmir Institute of Medical Sciences, Jhelum Valley Medical College, Bemina, Srinagar Kashmir, India and NABL accredited Dr. Qadri’s Haematology Center & Clinical Laboratory, Srinagar Kashmir, India and Sharda School of Medical Sciences & Research, Sharda Hospital, Greater Noida, UP, the distribution of which is follows:

<table>
<thead>
<tr>
<th>No.</th>
<th>Location</th>
<th>Isolates</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Urine</td>
<td>Wound/Pus</td>
</tr>
<tr>
<td>1.</td>
<td>SKIMS-JVC</td>
<td>64</td>
<td>16</td>
</tr>
<tr>
<td>2.</td>
<td>Qadri Hematology Lab.</td>
<td>59</td>
<td>12</td>
</tr>
<tr>
<td>3.</td>
<td>SMSR, Sharda University</td>
<td>29</td>
<td>08</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>152</td>
<td>36</td>
</tr>
</tbody>
</table>

The isolates were produced from the cultures of a variety of clinical samples taken from both in-patients and out-patients who were admitted to the hospitals from the aforementioned centres. By sub-culturing on MacConkey agar, all the bacterial cultures underwent a second test for viability and purity. (Figure 1).

Preliminary phenotypic and biochemical testing were conducted to validate the identity of isolates:

**Gram staining**

On a clean grease free slide, bacterial smears from 16-18 hrs were prepared, heat fixed and stained with Gram stain and observed under 100x oil immersion microscope.

**Motility test**

Motility of the organism was observed using hanging drop technique

**Catalase test**

On a clean grease free slide, a small amount of bacterial culture was mixed with drop of 3% H$_2$O$_2$. Appearance of effervescence is an indication of catalase positive otherwise negative.

**Oxidase test**

The culture was smeared on oxidase discs (Himedia) with the inoculation loop. Appearance of blue or purple color within 10 seconds in an indication or oxidase positive otherwise negative.

**Isolation of Presumptive ESBL producing *Escherichia coli***

Presumptive isolates were inoculated in nutritional broth and incubated at 37°C until the suspension met the 0.5McFarland standard (1.5x10$^8$ CFU/mL). Around 10µl of the suspension was spread using a sterile spreader on ESBL ChromoSelect Agar (Sigma-Aldrich) plates. The media was prepared by dissolving 40 grams in one liter of distilled water and heated to dissolve it completely. Sterilization of media was done by autoclaving at 15lbf pressure (121°C) for 15 minutes, cooled to 50°C and rehydrated contents of two vials of ESBL ChromoSelect Selective Supplement (Cat #61471, Sigma) was added,
mixed well and poured into sterile petri plates. From each plate two pink colonies were selected and then on nutrient agar slant colonies were streaked and then overnight incubation was done and kept at 4°C for further analysis (Figure 2).

**Phenotypic tests for the detection of ESBLs**

Use of disk diffusion test to check resistance to Ceftazidime and Cefotaxime by presumptive ESBL producing *E. coli*.

As recommended by Clinical and Laboratory Standards Institute (CLSI), the ESBL isolates underwent disc diffusion testing in order to check resistance against cefotaxime and ceftazidime (Figure 3). Each isolate was suspended in the nutrient broth and a suspension was made whose turbidity matches with 0.5 McFarland standard (1.5x10⁸ CFU/mL). The bacterial suspension was then spread on Mueller Hinton agar with a sterilised cotton swab to produce a uniform lawn culture. Antibiotics disc of cefotaxime and ceftazidime were placed on the surface of Muller Hinton agar plate after the plate had dried, and incubation was done for 18-24 hours at 37°C. Zone of inhibition around the discs were measured and recorded. For concluding resistance disk potency and inhibition zone diameters were used as shown in Table 2. Isolates were declared to be ESBL positive even if they show resistance to one of the antibiotic disc.
Confirmation of ESBL producing *E. coli* by Cephalosporin/Clavulanate combination disks

Double disc synergy test was performed as per CLSI guidelines in 2010 for those isolates which were resistant to one of the antibiotics viz. Cefotaxime and Ceftazidime. The isolates were grown in nutrient broth till they matched 0.5 McFarland standard (1.5x10^8 CFU/mL). Bacterial suspension was spread on the Muller Hinton agar plates uniformly. After the plates dry, antibiotic discs containing cefotaxime, cefotaxime+clavulanic acid and ceftazidime, ceftazidime+clavulanic acid were placed on the surface of the plates and incubated for 18-24 hours at 37°C. After overnight incubation and visible growth, zone of inhibition around the discs were measured and recorded. Increase in zone diameter of 5mm around the antibiotic disc containing cephalosporins and clavulanic acid over the antibiotic disc containing cephalosporin alone is an indicative of ESBL production (Figure 4).

**Etest for ESBLs**

HiMedia, India, makes plastic drug-impregnated strips which has gradient of antibiotic on both the sides with one end containing ceftazidime (MIC test range 0.5 to 32 µg/mL) and other end containing ceftazidime (MIC test range 0.064 to 4 µg/mL) and a fixed concentration of clavulanate (4 µg/mL). Similar strips of cefotaxime (MIC test range 0.25 to 16 µg/mL) and cefotaxime (MIC test range 0.016 to 1 µg/mL) plus a fixed concentration of clavulanate (4 µg/mL) are also available. Both screening and phenotypic confirmation of ESBL production was done by these strips. Pure cultures of bacteria cultivated overnight on MacConkey agar were

---

**Figure 4.** Phenotypic confirmation of ESBLs production in *E. coli* isolates by disk diffusion method using cefotaxime (CTX) and cefotaxime+clavulanic (CEC) acid disks

**Figure 5.** Phenotypic confirmation of ESBLs production in *E. coli* isolates by Etest using ceftazidime/ceftazidime + clavulanic acid Strip (Left) and cefotaxime/ceftaxime+clavulanic acid strip (Right)
used to create a suspension in nutrient broth that matched the 0.5 McFarland (1.5x10^8 CFU/mL) standard. Lawn culture was made on Muller Hinton agar with sterile cotton swab. The antibiotic impregnated strips were placed on Muller Hinton agar after the plates dry at desired position. The strips became absorbed and firmly attached to the agar surface after 60 seconds and plates were incubated for 18-24 hours at 37°C. Read the MIC at the point on the strip where the ellipse crossed the MIC scale. If the isolates displayed a 8-fold reduction in cephalosporin MICs in the presence of clavulanate, they were deemed to be phenotypically confirmed ESBLs (As per manufacturer's instructions (HiMedia) (Figure 5).

**Molecular characterization of ESBL producing E. coli isolates**

**Extraction of bacterial DNA**

After ESBL producers were identified phenotypically, isolates were subjected to molecular analysis. A loopful of bacterial growth was obtained from nutritional agar slants and suspended in 500 microliters (µL) of sterile distilled water in a 2 mL microcentrifuge tube. The DNA was then extracted using the snap and chill technique, which involves boiling colonies suspended in distilled water for 10 minutes to release the DNA, followed by 10 minutes of cooling on ice and 1 minute of 10,000 g centrifugation in a Table top microcentrifuge (Biofuge Stratus, Heraeus). Around 2 µL of the supernatant were utilized as the template for the polymerase chain reaction (PCR).

**Detection of ESBL producing E. coli isolates**

All the isolates that were phenotypically determined to produce ESBLs were subjected to multiplex PCR (m-PCR) testing using particular primers to check for the presence of the *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, and *bla*<sub>CTX-M</sub> genes. (Table 3). The PCR amplification was carried out in 25 µL reaction volumes in 0.2 mL thin walled PCR tubes (Eppendorf, Germany). The PCR mixture consists of DNA template, Go-green Master Mix (Promega, premixed ready-to-use solution containing Taq DNA polymerase derived from bacteria, dNTPs, MgCl₂ and reaction buffers), specific primers and Nuclease free water. Negative template control was sterile distilled water. The following cycling parameters were used during PCR in the Mastercycler Gradient Thermal cycler (Eppendorf, Germany): an initial denaturation at 95°C for 15 min; followed by 30 cycles of amplification each consisted of 30 s of denaturation at 94°C; 90 s of annealing at 62°C and 60 s of elongation at 72°C. The mixture was subjected to final elongation at 72°C for 10 min. The DNA extracted from the positive isolate maintained by the Division of Veterinary Microbiology and Immunology, SKUAST-Kashmir was included as positive control in the PCR reaction. Sterile distilled water was used as negative control. All the nucleotide primers used throughout the study were procured from Integrated DNA Technologies, USA.

### Table 2. Disk concentration and zone diameters for inferring resistance in the screening test

<table>
<thead>
<tr>
<th>Antibiotic disk</th>
<th>Resistant, if zone diameter was</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefotaxime-CTX (30 µg)</td>
<td>≤ 17 mm</td>
</tr>
<tr>
<td>Ceftazidime-CAZ (30 µg)</td>
<td>≤ 22 mm</td>
</tr>
</tbody>
</table>

### Table 3. Predicted amplicon length and a sequence of primers used to detect various beta-lactamase genes in multiplex PCR

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5’ - 3’)</th>
<th>Target gene</th>
<th>Amplicon size (bp)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>blaSHV</em>-F</td>
<td>CTT TATCGGCCCCTCACCTCAA</td>
<td><em>blaSHV</em></td>
<td>237</td>
<td>[8]</td>
</tr>
<tr>
<td><em>blaSHV</em>-R</td>
<td>AGGTGCTCATCATGGGAAG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>blaTEM</em>-F</td>
<td>CGCGCGTACACTATTTCTCAGAAT GA</td>
<td><em>blaTEM</em></td>
<td>445</td>
<td>[9]</td>
</tr>
<tr>
<td><em>blaTEM</em>-R</td>
<td>AGGTCACCAGGCTCCAGATTAT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>blaCTX-M</em>-F</td>
<td>ATGTGCAGYACCTAAARGTKATGCG</td>
<td><em>blaCTX-M</em></td>
<td>593</td>
<td>[10]</td>
</tr>
<tr>
<td><em>blaCTX-M</em>-R</td>
<td>TGGGTRAARARTGTSACCAAGAAYCAGCGG</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Electrophoresis and documentation

Agarose gel (1.5% w/v) was made by heating the appropriate amount of agarose (Sigma Aldrich, St. Louis, USA) with 40 mL 1X Tris acetate EDTA (TAE) buffer in a 500 mL Erlenmeyer flask. The flask was cooled to 60°C and ethidium bromide was added to the final concentration of 0.5µg/mL. The gel casting tray made of plastic was filled with warm agarose and a comb with 0.5 to 1mm wells was placed in the gel casting tray and allowed to set for around 30 minutes at room temperature. The comb was removed, and the gel was put on a Biometra electrophoresis tank that contained 1X TAE buffer. The wells in gel submerged in buffer tank were loaded with PCR products and standard molecular weight marker (Cat #DM003-R500, GeneDireX) was loaded in one well. The gel received a voltage of 5 V/cm across the ends until the yellow loading dye migrated to particular distance. The gel was removed carefully from the buffer and visualized under ultraviolet illumination and photographed with Gel Documentation System (BioDocAnalyze [BDA], Biometra, Germany) (Figure 6).

Antimicrobial susceptibility profile

Bacterial isolates found to be positive for ESBL genes by m-PCR, were tested for multi drug resistance by the Kirby Bauer disk diffusion method as per Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI, 2010) against 20 antibiotics (Table 4).

Statistical Analysis

Level of significance p<0.05 was done by analyzing data using students t-test.

Figure 6. Representative bla$_{SHV}$, bla$_{TEM}$ and bla$_{CTX-M}$ genes profile of phenotypically positive isolates using multiplex polymerase chain reaction (m-PCR): Lane M: 100 bp DNA Ladder; Lane 1: Positive control for bla$_{SHV}$, bla$_{TEM}$ and bla$_{CTX-M}$ genes; Lane 2: Negative control Lane 3: bla$_{SHV}$ positive; Lane 4: bla$_{TEM}$ positive; Lane 5: bla$_{CTX-M}$ positive; Lane 6: bla$_{TEM}$ and bla$_{CTX-M}$ positive and Lane 7: bla$_{SHV}$, bla$_{TEM}$ and bla$_{CTX-M}$ positive.

Figure 7. The overall incidence of ESBL genotypes in screening positive E. coli isolates.
RESULTS

ESBL screening of *E. coli*

The initial screening test of ESBL production by DDST and the phenotypic confirmation test revealed that 158 (or 75%) out of the 210 *E. coli* isolates were positive. Multiplex PCR was performed on all 158 phenotypically verified *E. coli* isolates using bacterial lysate as the template. Out of 158 ESBL isolates only 124 (78.48%) isolates carried the gene/s screened for blaTEM, blaCTX-M, and blaSHV genes. Isolates carrying blaSHV gene produced an amplicon of 237 bp, those carrying blaTEM showed an amplicon of 445 bp. The blaCTX-M gene produced an amplicon of 593bp. The multiplex PCR assay results indicated 45.16% blaTEM genes, 8.06% blaTEM/blaCTX-M genes, 34.16% blaCTX-M, 12.09% blaSHV, 16.90% blaCTX-M + blaSHV, 2.50% blaTEM + blaSHV. The overall incidence of ESBL genotypes in *E. coli* isolates is illustrated in (Figure 7).

Antimicrobial susceptibility profile

In total, 124 *E. coli* isolates were tested for their antimicrobial resistance profile against 20 different antimicrobial agents was tested. The prevalence of antimicrobial resistance among the ESBL positive strains isolated from various clinical isolates is shown in Table 4 against twenty antimicrobial agents and interpreted as resistant and sensitive following the guidelines of Clinical Laboratory Standard Institute Laboratory Standard Institute. Zone of inhibition were measured and the susceptibility (or resistance) of each isolate was determined (Figure 8 & 9).

DISCUSSION

Surveillance of antimicrobial resistance is very important for keeping track of community infections in order to understand how different treatment approaches affect resistance. The emergence and dissemination of resistance are due to the non-judicious use of antibiotics and
the resistance develops either by intrinsic way or acquired way.\textsuperscript{11}

One of the eight bacterial species WHO has singled out is \textit{E. coli} and is of particular concern for antibiotic resistance, serving as a sentinel organism which is responsible for developing resistance in urine and blood.\textsuperscript{1} There are significant regional and global differences in the incidence of ESBL among clinical isolates, and these differences are evolving quickly.\textsuperscript{12} The prevalence reported in our study (75%) which is in agreement with 61% by other studies Falgenhauer \textit{et al.}\textsuperscript{13}; 69.2% by Pouladfar \textit{et al.}\textsuperscript{14} and 72.9% by Mood \textit{et al.}\textsuperscript{15} and lower than reported by Ali \textit{et al.}\textsuperscript{16} (80%) and Kokabi \textit{et al.}\textsuperscript{17} (84.74%). In contrast, it is higher than those reported from Iran (26.6%) by Tabar \textit{et al.}\textsuperscript{18}; 34.6% by Naziri \textit{et al.}\textsuperscript{19}; 24.5% by Mohajeri \textit{et al.}\textsuperscript{20}; 41% by Hashemizadeh \textit{et al.}\textsuperscript{21} and 46.1% by Moosavian \textit{et al.}\textsuperscript{22}

The ESBL-positive \textit{E. coli} isolates investigated here showed higher frequency of \textit{bla}_{TEM} genes (45.16%) followed by \textit{bla}_{CTX-M} (34.67%), \textit{bla}_{SHV} (12.09%) and \textit{bla}_{TEM} + \textit{bla}_{CTX-M} genes (8.06%).

Our findings are consistent with those of Cristea \textit{et al.}\textsuperscript{23} who found 19.7% \textit{E. coli} isolates encoded for \textit{bla}_{SHV}. Furthermore, Sadeghi \textit{et al.}\textsuperscript{24} reported 38.8% isolates encoded for \textit{bla}_{CTX-M} and also Habeeb \textit{et al.}\textsuperscript{25} reported 42.5% isolates and 48.1% isolates of \textit{E. coli} encoded for \textit{bla}_{CTX-M} and \textit{bla}_{TEM} respectively.

In another report by Jena \textit{et al.},\textsuperscript{26} frequency of \textit{bla}_{TEM} was reported more than \textit{bla}_{CTX-M}, followed by \textit{bla}_{SHV} which is in close conformity to our findings.

Antibiotic resistance in \textit{E. coli} has been seen to rise across multiple drug classes in many investigations, and resistance to \textit{\beta}-lactam, cephalosporin, and carbapenem antibiotics is becoming more well-documented.\textsuperscript{11,27,28,29} The ESBL production is alarming. Our study showed a susceptibility of 100% for imipenem, this frequency was similar with other studies in which susceptibility varied from 95 up to 100% for imipenem.\textsuperscript{18,20,25,30,31,36} We have few options for treating severe infections because of the significant rise in \textit{\beta}-lactamase production, which includes the high level of ESBL producers. In this study, the ESBL strains showed high resistance to ampicillin (100%), aztreonam (78.5%), cepheim (100%), ceftriaxone (86.6%), tetracycline (66.66%), norfloxacin (50%) and nitrofurantoin (8.33%), which is consistent with a claim made by Cristea \textit{et al} in Romania.\textsuperscript{23} and also observed in other studies.\textsuperscript{31-34} Most of the therapeutic problem are associated with ESBL strains due to their resistant against broad spectrum antibiotics including third generation cephalosporins. These strains also have the potential for plasmid-mediated quinolone (PMQR) and carbapenem resistance. MDR Multiple Drug Resistance is also responsible

\textbf{Figure 8.} Antimicrobial sensitivity pattern of ESBL isolates against aztreonam (ATM 30µg); ceftriaxone (CRO 30µg); chloramphenicol (C 30µg); imipenem (IMP 10µg) and nalidixic acid (NA 30 µg)

\textbf{Figure 9.} Antimicrobial sensitivity pattern of ESBL isolates against tetracycline (TE 30µg); norfloxacin (NX 10µg); ciprofloxacin (C 5µg); streptomycin (S 10µg), furazolidone (FR 50 µg) and co-trimoxazole (COT 25µg)
for creating complications in level of resistance leading to overprescribing of antibiotics in healthcare settings without prior microbiologic testing.\textsuperscript{35,36}

CONCLUSION

The high prevalence of ESBL-producing \textit{E. coli} isolates in clinical samples indicates the urgent need for appropriate infection control restrictions. The identification of \textit{bla}\textsubscript{TEM} as the most prevalent gene in these isolates highlights the need for further research to determine the molecular epidemiology of ESBL-producing \textit{E. coli}. The high levels of resistance to commonly used antibiotics, such as ampicillin, doxycycline, cefixime and gentamicin, underscore the importance of prudent use of antibiotics to reduce the selection pressure on resistant strains. The findings of this study provide valuable insights into the prevailing trends of ESBL-producing \textit{E. coli} in the region and can help in the development of effective prevention and control strategies.

ACKNOWLEDGMENTS

The authors would like to thank Department of Microbiology, SMSR Sharda University, Department of Microbiology, JVC SKIMS and Qadri Hematology Laboratory for providing clinical isolates. Authors are thankful to the whole team of Department of Veterinary Microbiology \\& Immunology, SKUAST-K for their immense help and altruistic co-operation for providing laboratory support during the research. The authors also acknowledge the support for research (consumables etc.,) provided under grant from Centre for public health UNMC, Nebraska USA to Department of Veterinary Microbiology \\& Immunology SKUAST-K. Authors are also thankful to the technicians and office staff of the above prestigious institutes for their guidance and support in this project.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORS’ CONTRIBUTION

HAS, MAB, DKK conceptualized the study. SF, ASY, ASH helped in research conduction and sampling. SQ, BN and AT wrote the manuscript. All authors read and approved the final manuscript for publication.

FUNDING

None.

DATA AVAILABILITY

All datasets generated or analyzed during this study are included in the manuscript.

ETHICS STATEMENT

Not applicable.

REFERENCES


Journal of Pure and Applied Microbiology
